My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany
   Program
   Abstracts


1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version

Friday June 19
08:00-08:40 Registration and coffee
08:40-09:00 Welcome and Introduction
Oral session I Compliance and non-parametric modelling chair: Leon Aarons
09:00-09:30 J.M. Gries Estimation of individual pharmacokinetic parameters in the presence of possible non-compliance
09:30-10:00 D. Verotta Mechanistic and non-mechanistic drug dynamics modeling
10:00-11:30 Poster and software session I
Oral session II Regulatory perspective chair: Janet Wade
11:30-12:00 R. Shah Limitations of population approaches in regulatory assessment of new chemical entities.
12:00-12:30 J. Wade Miscellaneous regulatory information
12:30-14:00 Lunch
Oral session III Clinical applications chair: Karin Fattinger
14:00-14:20 M. McFadyen Clinical versus statistical significance in covariate selection
14:20-14:40 R. Gomeni Circadian population pharmacokinetics of 5-Fluorouracil in patients with metastatic colorectal cancer
14:40-15:00 K. Kozlowski Semi-population model for analysis of infusable immunoglobin-G pharmacokinetics in VLBW infants
15:00-15:20 S. Marshall Do we require the population approach to dose adjust in renal impairment?: A case study with dofetilide
15:20-16:10 Coffee/Tea
Oral session IV Methodology chair: Mats Karlsson
16:10-16:30 S. Duffull Comparison of a semiparametric method with NONMEM for population analysis of simulated data
16:30-17:00 J. Wakefield The analysis of ordinal pharmacodynamic data: application to allergy score
17:00-17:30 G. Graham A bayesian analysis of categorical and count pharmacodynamic data
19:00- 00:10 Social event Gut Höhne

Saturday June 20
Oral session V Methodology chair: Nick Holford
09:00-09:20 M. Karlsson An automated stepwise covariate model building procedure within NONMEM
09:20-09:40 R. Schoemaker Estimating potency for the Emax-model without attaining maximal effects
09:40-10:00 S. Laporte What is the relevance of estimating inter-study variability in population pharmacokinetic meta-analysis?
10:00-10:30  J.L. Steimer  Mixed-effects modelling and simulation of the Dose-AUC relationship of saquinavir in healthy subjects and HIV-positive patients (II)
10:30-12:00 Poster and software session II
Oral session VI Clinical trial simulation chair: Christian Pobel
12:00-12:30 J. Mandema Dose ranging trials in detrusor instability with Tolterodine
12:30-13:00 N. Holford Clinical Pharmacology = Disease Progress + Drug Action. The role of clinical trial modelling, simulation and analysis using the population PKPD approach
13:00-13:30 M. Berahee An integrated population PK-PD model characterising the time course of exposure and clinical endpoints (biochemical, physiological and haemodynamics) for 546C88, a nitric oxide synthase inhibitor, in patients with septic shock
13:30-13:40 Closure followed by light lunch

Poster session I
 
GE Blakey, P McCormack, ADP Dean, N Entwistle An exploratory population pharmacokinetic analysis examining the influence of demography and co-medication on the plasma clearance of the anti-epileptic remacemide
S Chabaud, P Girard, P Nony , C. Laveille, JP Boissel PK-PD model of ivabradine, a bradzcardic agent, and ets metabolite in healthz volunteers
F Ezzet Population pharmacokinetics and therapeutic response of artemether following treatment of coartem in malaria patients
N Frey, M Dubar, JMA van Gervan, R Jochemsen Population pharmacokinetics/pharmacodynamics of rilmenidine in 27 hypertensive patients
JM Lanao, S Romano, MM Fdez De Gatta, MV Calvo, D Caballero, A Dominguez-Gil Population pharmacokinetics of amikacin in hematologic patients
P McCormack, L Aarons, N Yeates, M Nassim, J Gardner, M Russell Pharmacokinetic and pharmacodynamics of AR-C69931MX a novel P2T antagonist in healthy male and female volunteers
P Mismetti, S Laporte, P Girard, H Decousus Indirect pharmacodynamic model with two different markers of oral antocoagulant in young healthy volunteers
D Santos Buelga, G Frutos, MJ Garcia, MJ Otero, A Dominguez-Gil Optimization of a population pharmacokinetic model of theophylline in adult patients
N Simon, E Fuseau, P Daley-Yates Fluticasone propionate pharmacokinetics in asthma patients when administered alone or in combination to salmeterol
N Taright, F Mentré, P Engrand, F Loumaye, I Trinchard-Lugan, A Munafo Population pharmacokinetics of recombinant human luteinising hormone in patients
M Costa, E Berno, GP Zara, C Della Pepa, R Canaparo, M Eandi A non-parametric population PK/PD analysis of tolcapone to predict L-Dopa plasma concentrations

Poster session II
 
MJ García, D Santos Buelga, MJ Otero, B Blanco, AC Falcão, A Domínguez-Gil Therapeutic drug monitoring of antiepileptic drugs; can we use tdm data to estimate population pharmacokinetic parameters?
P Ghahramani, WW Yeo, GT Tucker Use of NONMEM to determine the influence of CYP2D6 activity on the pharmacokinetics of amitriptyline and nortriptyline
G Hempel, MO Karlsson, DP de Alwis, J McNay, N Toublanc, HG Schaefer Population PK/PD Modelling of 24h-Ambulatory Blood Pressure Data using NONMEM
M Van Guilder, R Leary, A Schumitzky, X Wang, S Vinks, R Jelliffe Nonlinear nonparametric population modeling on a supercomputer
I Meineke Modelling interoccasion variability after repeated oral drug administration
Y Merlé, E Schmautz, A Mallet Assessment of two strategies for detecting pharmacodynamic interactions in the context of the npml approach; Role of the design and of the interindividual variability
I Nestorov, L Aarons, M Rowland A population approach to the study of structure-pharmacokinetic relationships: An example with a homologous series of barbiturates
L Nguyen, P Variol, B Tranchand, C Puozzo Population pharmacokinetics of Navelbine : Model set up from phase I data and Validation of a limiting sampling strategy
P Noertersheuser, S Ghani, S Kreis Evaluation of the dose / concentration / response relationship of an antithrombotic acting development drug, performed with NONMEM and P - PHARM
U Wählby, EN Jonsson, MO Karlsson A stepwise procedure for interindividual variability model building
P Williams, J Lane, E Capparelli, C Turkel Computer Simulation: A Useful Tool for Trial Dosage Selection